SGC-CBP30

TargetMol
Product Code: TAR-T6668
Supplier: TargetMol
CodeSizePrice
TAR-T6668-1mg1mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6668-2mg2mg£123.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6668-5mg5mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6668-1mL1 mL * 10 mM (in DMSO)£143.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6668-10mg10mg£168.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6668-25mg25mg£249.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6668-50mg50mg£369.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6668-100mg100mg£517.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).
CAS:
1613695-14-9
Formula:
C28H33ClN4O3
Molecular Weight:
509.05
Pathway:
Chromatin/Epigenetic
Purity:
0.9903
SMILES:
COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl
Target:
Epigenetic Reader Domain; Histone Acetyltransferase

References

Gendarme M, Baumann J, Ignashkova T I, et al. Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1[J]. Molecular biology of the cell. 2017 Dec 15;28(26):3756-3772. Wellinger L C, Hogg S J, Newman D M, et al. BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity. Cancer Immunology Research. 2022, 10(1): 87-107. Gendarme M, Baumann J, Ignashkova T I, et al. Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1. Molecular Biology of the Cell. 2017 Dec 15;28(26):3756-3772 Wellinger L C, Hogg S J, Newman D M, et al. Bet inhibition enhances TNF-mediated antitumor immunity. Cancer Immunology Research. 2022, 10(1): 87-107 Structural Genomics Consortium Wellinger L C, Hogg S J, Newman D M, et al. BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity[J]. bioRxiv. 2021 Liu L, Deng P, Liu S, et al.Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma.Cell Death & Disease.2023, 14(8): 513. Pan X, Zhang W, Wang L, et al.KLF12 transcriptionally regulates PD?L1 expression in non?small cell lung cancer.Molecular Oncology.2023